Analysts Set Amicus Therapeutics, Inc. (FOLD) Price Target at $19.32

Share on StockTwits

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has earned a consensus recommendation of “Hold” from the eight ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $19.32.

Several equities analysts have commented on FOLD shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $20.00 target price on shares of Amicus Therapeutics in a research report on Tuesday, February 5th. ValuEngine lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, February 5th. Zacks Investment Research upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 4th. Citigroup upgraded Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $12.59 target price on the stock in a report on Wednesday, January 16th. Finally, BidaskClub upgraded Amicus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, January 4th.

In related news, CEO John F. Crowley sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $12.12, for a total value of $242,400.00. Following the transaction, the chief executive officer now directly owns 688,081 shares of the company’s stock, valued at approximately $8,339,541.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John F. Crowley sold 103,500 shares of the company’s stock in a transaction that occurred on Tuesday, January 15th. The shares were sold at an average price of $11.71, for a total value of $1,211,985.00. Following the completion of the transaction, the chief executive officer now directly owns 771,581 shares in the company, valued at $9,035,213.51. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 212,769 shares of company stock worth $2,520,371. 2.90% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can increased its stake in Amicus Therapeutics by 117.9% in the 4th quarter. Bank of Montreal Can now owns 3,428 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,855 shares in the last quarter. Strs Ohio lifted its holdings in shares of Amicus Therapeutics by 56.0% in the 4th quarter. Strs Ohio now owns 3,900 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,400 shares during the last quarter. Sage Capital Advisors llc lifted its stake in Amicus Therapeutics by 13.8% in the fourth quarter. Sage Capital Advisors llc now owns 12,400 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 1,500 shares during the last quarter. Tower Research Capital LLC TRC bought a new stake in Amicus Therapeutics in the third quarter worth about $159,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Amicus Therapeutics in the third quarter worth about $172,000.

NASDAQ FOLD traded up $0.17 on Friday, reaching $11.14. The stock had a trading volume of 139,937 shares, compared to its average volume of 3,146,604. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.12 and a quick ratio of 9.03. Amicus Therapeutics has a 1-year low of $8.27 and a 1-year high of $17.62. The firm has a market cap of $2.08 billion, a price-to-earnings ratio of -3.84 and a beta of 1.77.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Featured Story: Average Daily Trade Volume – What It Means In Stock Trading

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Critical Review: COBHAM PLC/ADR  & ORIENTAL LD CO/ADR
Critical Review: COBHAM PLC/ADR & ORIENTAL LD CO/ADR
Haverty Furniture Companies  Hits New 12-Month High After Better-Than-Expected Earnings
Haverty Furniture Companies Hits New 12-Month High After Better-Than-Expected Earnings
Summit Materials  Shares Up 7.4% Following Insider Buying Activity
Summit Materials Shares Up 7.4% Following Insider Buying Activity
Ascential’s  “Buy” Rating Reaffirmed at Shore Capital
Ascential’s “Buy” Rating Reaffirmed at Shore Capital
Centrica  Downgraded to Hold at Berenberg Bank
Centrica Downgraded to Hold at Berenberg Bank
Peel Hunt Boosts Future  Price Target to GBX 660
Peel Hunt Boosts Future Price Target to GBX 660


Leave a Reply

© 2006-2019 Ticker Report